18
187420.KQ GenoFocus Inc
- Market cap
- KRW 77.0B
- P/E
- 7.9x
- P/B
- 1.43x
- ROE
- 14.8%
- Dividend yield
- -
- Fundamental score
- 2.7/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 187420.KQ undervalued?
Graham number187420.KQ trades 29.0% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GenoFocus Inc fundamental analysis
13 of 22 checks passedROE 1/2
Moderate return on equity (14.8%), between 10% and 20%.
ROA 1/1
Return on assets (5.8%) is above the industry median (4.7%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (219.0%) is above the industry median (-16.9%).
Revenue Growth 2/2
Revenue grew 16.0% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (10.5%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 0/1
EBIT is 1.8x against interest expense, below 5x.
PE vs Market 1/1
PE (7.9x) is below the market median (11.3x).
PE vs Industry 1/1
PE (7.9x) is below the industry median (9.1x).
PBV 0/1
Price to book (1.4x) is above the industry median (0.6x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 11.3, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
GenoFocus Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GenoFocus Inc
HLB Genex, Inc. engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally. Its industrial special enzyme products include lactase; catalase for use in semiconductor industry; and proteinase K for molecular diagnostics and genetic engineering experiments, as well as bio-health care ingredients comprise N-phytosphingosine and vitamin K2. The company also develops drug candidates for wet …
Full company profileGenoFocus Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GenoFocus Inc annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 7.03B | 11.5B | 11.5B | 14.9B | 18.8B | 25.9B | 27.8B | 27.0B | 35.4B | 43.4B | 46.0B |
| Gross Profit | 3.00B | 3.39B | 1.59B | 3.70B | 6.06B | 9.83B | 10.2B | 7.33B | 14.3B | 15.2B | 19.3B |
| Operating Income | 1.33B | 360M | -3.11B | -4.89B | -8.35B | -3.83B | -7.20B | 498M | -621M | 1.28B | 4.05B |
| EBITDA | - | - | - | - | - | - | -566M | 9.36B | -8.15B | 39.4B | 22.0B |
| Net Income | 1.61B | 1.41B | -2.32B | -5.76B | -12.2B | -6.82B | -13.0B | -2.95B | -18.8B | 22.6B | 8.02B |
| EPS | 82 | 71 | -106 | -260 | -545 | -303 | -576 | -130 | -646 | 769 | 273 |
| Balance Sheet | |||||||||||
| Total Assets | 63.2B | 70.2B | 70.3B | 90.2B | 113B | 119B | 134B | 97.9B | 146B | 136B | 138B |
| Total Liabilities | 710M | 5.93B | 10.1B | 38.1B | 73.5B | 83.2B | 110B | 71.5B | 122B | 81.1B | 69.5B |
| Shareholders' Equity | 62.5B | 64.2B | 60.2B | 52.1B | 39.8B | 35.3B | 23.9B | 22.0B | 23.8B | 40.9B | 54.0B |
| Cash & Short-term Investments | 35.8B | 23.3B | 8.25B | 22.0B | 35.6B | 25.6B | 41.5B | 29.9B | 83.8B | 33.5B | 35.8B |
| Total Debt | - | 2.60B | 5.64B | 28.1B | 33.4B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 516M | 1.36B | 1.56B | -167M | -2.45B | -2.39B | -4.71B | -4.82B | 2.87B | 3.50B | 5.90B |
| Capital Expenditure | 5.46B | 2.06B | 7.42B | 8.43B | 14.3B | 9.35B | 4.32B | 1.33B | 699M | 1.08B | 1.97B |
| Free Cash Flow | - | - | - | - | -18.1B | -11.7B | -9.03B | -6.15B | 2.17B | 2.43B | 3.94B |
| Ratios | |||||||||||
| ROE | 2.6% | 2.2% | -3.8% | -11.0% | -30.7% | -19.3% | -54.3% | -13.4% | -79.2% | 55.2% | 14.8% |
| ROA | 2.6% | 2.0% | -3.3% | -6.4% | -10.8% | -5.8% | -9.7% | -3.0% | -12.9% | 16.6% | 5.8% |
| Net Profit Margin | 23.0% | 12.3% | -20.1% | -38.5% | -65.1% | -26.3% | -46.6% | -10.9% | -53.1% | 52.1% | 17.4% |
| Debt to Equity | - | 0.04x | 0.09x | 0.54x | 0.84x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
GenoFocus Inc dividends
GenoFocus Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 2:1 on Mar 19, 2018.
Who owns GenoFocus Inc
- Insiders 35.44%
- Institutions 0.00%
- Public & others 64.56%
- Shares outstanding 32.6M
- Free float 21.4M
GenoFocus Inc company profile
- Company name
- GenoFocus Inc
- Ticker
- 187420.KQ
- ISIN
- KR7187420005
- Exchange
- KOSDAQ
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 74
- Fiscal year end
- December
- Address
- 65 Techno 1-ro, Daejeon, South Korea, 34014
- Phone
- 82 4 2862 4483
- Website
- hlbgenex.com
About GenoFocus Inc
HLB Genex, Inc. engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally. Its industrial special enzyme products include lactase; catalase for use in semiconductor industry; and proteinase K for molecular diagnostics and genetic engineering experiments, as well as bio-health care ingredients comprise N-phytosphingosine and vitamin K2. The company also develops drug candidates for wet and dry macular degeneration, inflammatory bowel disease, anticancer, oral mucositis, nonalcoholic steatohepatitis, diabetic macular edema, and dry eye indications. The company was formerly known as GenoFocus, Inc. HLB Genex, Inc. was founded in 2000 and is based in Daejeon, South Korea.
GenoFocus Inc management
2- Mr. Eui-Joong KimChief Executive Officer
- Jae-Gu PanFounder & CTO